Endometriosis - Pipeline Review, H2 2020
Endometriosis - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2020, provides an overview of the Endometriosis (Women's Health) pipeline landscape.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 12, 1, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.
Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2020, provides an overview of the Endometriosis (Women's Health) pipeline landscape.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 12, 1, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.
Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Endometriosis - Overview
Endometriosis - Therapeutics Development
Endometriosis - Therapeutics Assessment
Endometriosis - Companies Involved in Therapeutics Development
Endometriosis - Drug Profiles
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Appendix
Endometriosis - Overview
Endometriosis - Therapeutics Development
Endometriosis - Therapeutics Assessment
Endometriosis - Companies Involved in Therapeutics Development
Endometriosis - Drug Profiles
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Endometriosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Endometriosis - Pipeline by Adynxx Inc, H2 2020
Endometriosis - Pipeline by Aptorum Group Ltd, H2 2020
Endometriosis - Pipeline by ARTham Therapeutics Inc, H2 2020
Endometriosis - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Endometriosis - Pipeline by Bayer AG, H2 2020
Endometriosis - Pipeline by Bol Pharma, H2 2020
Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Endometriosis - Pipeline by Context Therapeutics LLC, H2 2020
Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2020
Endometriosis - Pipeline by Enteris BioPharma Inc, H2 2020
Endometriosis - Pipeline by Eurofarma Laboratorios SA, H2 2020
Endometriosis - Dormant Projects, H2 2020
Endometriosis - Discontinued Products, H2 2020
Number of Products under Development for Endometriosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Endometriosis - Pipeline by Adynxx Inc, H2 2020
Endometriosis - Pipeline by Aptorum Group Ltd, H2 2020
Endometriosis - Pipeline by ARTham Therapeutics Inc, H2 2020
Endometriosis - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Endometriosis - Pipeline by Bayer AG, H2 2020
Endometriosis - Pipeline by Bol Pharma, H2 2020
Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2020
Endometriosis - Pipeline by Context Therapeutics LLC, H2 2020
Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2020
Endometriosis - Pipeline by Enteris BioPharma Inc, H2 2020
Endometriosis - Pipeline by Eurofarma Laboratorios SA, H2 2020
Endometriosis - Dormant Projects, H2 2020
Endometriosis - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Endometriosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Endometriosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
